Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Li, Qing; Xiang, Ming

doi:10.1038/s41401-021-00776-4

Cited by 16 publications

(15 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 483 This transient myelopoiesis is terminated after the stimulus is removed, and myeloid cell homeostasis is then restored. 484 However, in chronic inflammation, cancer, and autoimmune diseases, persistent myelopoiesis may occur to prevent widespread tissue damage of the host, constantly generating IMCs. These cells have distinct characteristics, such as immature phenotype and morphology, relatively weak phagocytic function, and anti-inflammatory and immunosuppressive functions, 485 matching their descriptive name.…”

Section: Targeting the Suppressive Tmementioning

confidence: 99%

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Wang

Sun

2022

Sig Transduct Target Ther

178

114

View full text Add to dashboard Cite

Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors. Represented by immune checkpoint blockade and adoptive cell transfer, tumor immunotherapy has seen tremendous success in the clinic, with the capability to induce long-term regression of some tumors that are refractory to all other treatments. Among them, immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4 inhibitors (ipilimumab), has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer (NSCLC) and melanoma. In addition, with the advent of CAR-T, CAR-M and other novel immunotherapy methods, immunotherapy has entered a new era. At present, evidence indicates that the combination of multiple immunotherapy methods may be one way to improve the therapeutic effect. However, the overall clinical response rate of tumor immunotherapy still needs improvement, which warrants the development of novel therapeutic designs as well as the discovery of biomarkers that can guide the prescription of these agents. Learning from the past success and failure of both clinical and basic research is critical for the rational design of studies in the future. In this article, we describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.

show abstract

Section: Targeting the Suppressive Tmementioning

confidence: 99%

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Wang

Sun

2022

Sig Transduct Target Ther

178

114

View full text Add to dashboard Cite

show abstract

“…MDSCs are important in the development of tumors and various autoimmune disease. [64] Circulating CD14 + CD15 -CD11b + HLA-DR -M-MDSCs are dramatically increased in ACLF patients. These M-MDSCs down-regulate immune response by reducing T cell proliferation and declining the production of IL-6 and TNF-a in answer to TLR activation.…”

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 97%

“…MDSCs perform this inhibitory effect through various mechanisms, including suppression of T cells proliferation, antibody and IFN-γ production, and induction of regulatory T (Treg) cell populations. MDSCs are important in the development of tumors and various autoimmune disease [64] . Circulating CD14 + CD15 - CD11b + HLA-DR - M-MDSCs are dramatically increased in ACLF patients.…”

Section: Innate Immune Cells In Achblfmentioning

confidence: 99%

Current Advances of Innate and Adaptive Immunity in Acute-on-Chronic Hepatitis B Liver Failure

Wang

Fan

2022

Infectious Diseases &Amp; Immunity

View full text Add to dashboard Cite

Acute-on-chronic hepatitis B liver failure (ACHBLF) is a term used to define the acute deterioration of liver function that occurs in patients with chronic hepatitis B virus infection or hepatitis B virus-related liver cirrhosis. The specific pathogenesis of ACHBLF is still not completely understood. Current research has shown that an intense systemic inflammation is involved in the development of acute-on-chronic liver failure (ACLF). Meanwhile, a subsequent immune paresis over the course of ACLF favors the development of infection and sepsis. Deregulation in both the innate and adaptive immunity is the notable feature of ACLF. The dysregulated immune responses play a crucial role in disease progression and potentially drive organ failure and mortality in ACHBLF. In this review, we highlight the current knowledge of innate and adaptive immune cells in ACHBLF.

show abstract

“…MDSCs represent the most significant immunosuppressive cellular population in individuals with lung tumours. In the stroma of the tumour, these cells limit the healing efficacy of anti-cancer curing approaches through their metabolic pathways and other modalities in response to complex TME ( 39 ).There are many clinical studies on MDSCs in lung tumours, and therapeutic strategies targeting MDSCs are also gradually emerging. We have summarized these clinical studies and presented them in Table 1 .…”

Section: The Roles Of Myeloid-derived Suppressor Cells (Mdscs) In Lun...mentioning

confidence: 99%

LncRNAs has been identified as regulators of Myeloid-derived suppressor cells in lung cancer

et al. 2023

View full text Add to dashboard Cite

Lung tumours are widespread pathological conditions that attract much attention due to their high incidence of death. The immune system contributes to the progression of these diseases, especially non-small cell lung cancer, resulting in the fast evolution of immune-targeted therapy. Myeloid-derived suppressor cells (MDSCs) have been suggested to promote the progression of cancer in the lungs by suppressing the immune response through various mechanisms. Herein, we summarized the clinical studies on lung cancer related to MDSCs. However, it is noteworthy to mention the discovery of long non-coding RNAs (lncRNAs) that had different phenotypes and could regulate MDSCs in lung cancer. Therefore, by reviewing the different phenotypes of lncRNAs and their regulation on MDSCs, we summarized the lncRNAs’ impact on the progression of lung tumours. Data highlight LncRNAs as anti-cancer agents. Hence, we aim to discuss their possibilities to inhibit tumour growth and trigger the development of immunosuppressive factors such as MDSCs in lung cancer through the regulation of lncRNAs. The ultimate purpose is to propose novel and efficient therapy methods for curing patients with lung tumours.

show abstract

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Cited by 16 publications

References 138 publications

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Current Advances of Innate and Adaptive Immunity in Acute-on-Chronic Hepatitis B Liver Failure

LncRNAs has been identified as regulators of Myeloid-derived suppressor cells in lung cancer

Contact Info

Product

Resources

About